Oct 12 (Reuters) - Bausch Health Companies Inc BHC.TO :
* BAUSCH HEALTH LICENSES EYENOVIA'S INVESTIGATIONAL TREATMENT FOR THE REDUCTION OF PEDIATRIC MYOPIA PROGRESSION IN CHILDREN AGES 3-12
* BAUSCH HEALTH COMPANIES - AFFILIATE ACQUIRED LICENSE FOR DEVELOPMENT, COMMERCIALIZATION OF INVESTIGATIONAL FORMULATION OF ATROPINE OPHTHALMIC SOLUTION
* BAUSCH HEALTH COMPANIES INC - BAUSCH HEALTH WILL MAKE AN UPFRONT $10 MILLION PAYMENT TO EYENOVIA UPON SIGNING
* BAUSCH HEALTH COMPANIES INC - WILL ASSUME OVERSIGHT AND COSTS RELATED TO ONGOING PHASE 3 CHAPERONE CLINICAL TRIAL
* BAUSCH HEALTH COMPANIES INC - EYENOVIA ELIGIBLE TO RECEIVE UP TO $35 MILLION IN ADDITIONAL PAYMENTS BASED ON APPROVAL- AND LAUNCH-BASED MILESTONES
* BAUSCH HEALTH COMPANIES - EYENOVIA ELIGIBLE TO RECEIVE ROYALTIES RANGING FROM MID-SINGLE DIGIT TO MID-TEEN PERCENTAGES OF GROSS PROFIT ON SALES